Modulation of the Meisenheimer complex metabolism of nitro-benzothiazinones by targeted C-6 substitution

Author:

Keiff FrançoisORCID,Bernal Freddy A.ORCID,Joch Melanie,Jacques dit Lapierre Thibault J. W.ORCID,Li Yan,Liebing PhilORCID,Dahse Hans-Martin,Vilotijevic IvanORCID,Kloss FlorianORCID

Abstract

AbstractTuberculosis, caused by Mycobacterium tuberculosis, remains a major public health concern, demanding new antibiotics with innovative therapeutic principles due to the emergence of resistant strains. Benzothiazinones (BTZs) have been developed to address this problem. However, an unprecedented in vivo biotransformation of BTZs to hydride-Meisenheimer complexes has recently been discovered. Herein, we present a study of the influence of electron-withdrawing groups on the propensity of HMC formation in whole cells for a series of C-6-substituted BTZs obtained through reductive fluorocarbonylation as a late-stage functionalization key step. Gibbs free energy of reaction and Mulliken charges and Fukui indices on C-5 at quantum mechanics level were found as good indicators of in vitro HMC formation propensity. These results provide a first blueprint for the evaluation of HMC formation in drug development and set the stage for rational pharmacokinetic optimization of BTZs and similar drug candidates.

Funder

Bundesministerium für Bildung und Forschung

Publisher

Springer Science and Business Media LLC

Reference46 articles.

1. World Health Organization. Global Tuberculosis Report 2022. (2022).

2. World Health Organization. WHO Consolidated Guidelines on Tuberculosis Module 4: Treatment Drug-Susceptible Tuberculosis Treatment. (2022).

3. Furin, J., Cox, H. & Pai, M. Tuberculosis. Lancet 393, 1642–1656 (2019).

4. Fekadu, G., Tolossa, T., Turi, E., Bekele, F. & Fetensa, G. Pretomanid development and its clinical roles in treating tuberculosis. J. Glob. Antimicrob. Resist. 31, 175–184 (2022).

5. World Health Organization. WHO Operational Handbook on Tuberculosis Module 4: Treatment Drug-Resistant Tuberculosis Treatment. (2020).

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3